Journal of Medicine Says HCQ + Zinc Reduces COVID Deaths
Early on in the COVID-19 pandemic, doctors around the world reported high success rates using an inexpensive treatment protocol of hydroxychloroquine (HCQ) and zinc, typically in combination with an antibiotic to treat secondary bacterial infections.
Almost immediately, government health agencies and mainstream media started attacking the treatment, going so far as to ban the prescription and use of HCQ for COVID-19 in some areas. Over time, it became painfully clear that a concerted and coordinated effort to prevent its use was afoot.
One of the most obvious reasons for why certain individuals and companies might want to prevent the use of an inexpensive generic drug is because it might eliminate the need for a vaccine or other antiviral medication under development.1 Hundreds of millions of dollars have been invested, and drug companies were, and still are, counting on a massive payday. As noted by Dr. Meryl Nass in a June 27, 2020, blog post:2
“Hydroxychloroquine has been used safely for 65 years in many millions of patients. And so the message was crafted that the drug is safe for its other uses, but dangerous when used for COVID-19. It doesn’t make sense, but it seems to have worked. Were these acts carefully orchestrated? …
Might these events have been planned to keep the pandemic going? To sell expensive drugs and vaccines to a captive population? Could these acts result in prolonged economic and social hardship, eventually transferring wealth from the middle class to the very rich?”
Politicizing Medicine Has Grave Consequences
The fight over HCQ also appears to have had political underpinnings, and by politicizing medicine, the media has played a role that can readily be likened to agents of genocide. There’s no telling how many lives may have been saved had they done their due diligence and reported the science truthfully.
Most of us in the holistic field have been aware that the intent of censorship is to mislead people. After all, a majority of news outlets rely on revenue from advertisers, and drug companies tend to spend the most. As a result, what the drug industry wants is what the media deliver.
During this pandemic, conventional doctors have gotten a taste of what it’s like as well and, clearly, many have been absolutely floored by it. It’s certainly understandable, because to censor potentially lifesaving medical treatment during a global pandemic really brings it to a whole new level of evil.
As just one example among many, July 23, 2020, Dr. Harvey A. Risch, professor of epidemiology at Yale School of Public Health, published an op-ed in Newsweek in which he expressed his dismay and frustration:3
“I have authored over 300 peer-reviewed publications and currently hold senior positions on the editorial boards of several leading journals.
I am usually accustomed to advocating for positions within the mainstream of medicine, so have been flummoxed to find that, in the midst of a crisis, I am fighting for a treatment that the data fully support but which, for reasons having nothing to do with a correct understanding of the science, has been pushed to the sidelines.
As a result, tens of thousands of patients with COVID-19 are dying unnecessarily … I am referring, of course, to the medication hydroxychloroquine.
When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, especially when given in combination with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.”
In what appears to be an effort to change the tide, a medical review4 in the January 2021 issue of The American Journal of Medicine now urges early use of HCQ and zinc. The authors include Risch, as well as a long list of medical doctors from hospitals around the world.
The Importance of Early Outpatient Treatment
Risch’s paper, “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,” points out that:5
“In the absence of clinical trial results, physicians must use what has been learned about the pathophysiology of SARS-CoV-2 infection in determining early outpatient treatment of the illness with the aim of preventing hospitalization or death …
Therapeutic approaches based on these principles include 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy, and 5) administration of oxygen, monitoring, and telemedicine.”
The authors stress that “Most patients who arrive to the hospital … with COVID-19 do not initially require forms of advanced medical care,” and that, therefore, “it is conceivable that some, if not a majority, of hospitalizations could be avoided with a treat-at-home first approach.”
They also stress that since it can take up to a week to get PCR test results back, it’s important to start treatment before results are known. “For patients with cardinal features of the syndrome (i.e., fever, body aches, nasal congestion, loss of taste and smell, etc.) … treatment can be the same as those with confirmed COVID-19,” they say.
The Case for HCQ and Zinc
In terms of early drug treatment for patients who are quarantining at home, the authors recommend using a combination of HCQ and zinc lozenges, along with several other drugs (depending on your symptoms).
While I will review those here, keep in mind that I do not necessarily recommend using all of them, as in some cases there are safer alternatives. At the end of this article, I will summarize my personal at-home treatment recommendation, which I believe is among the absolute safest and most effective.
That said, in his paper, Risch and his co-authors explain the rationale for using HCQ and zinc as follows:6
“Hydroxychloroquine (HCQ) is an antimalarial/anti-inflammatory drug that impairs endosomal transfer of virions within human cells. HCQ is also a zinc ionophore that conveys zinc intracellularly to block the SARS-CoV-2 RNA-dependent RNA polymerase, which is the core enzyme of the virus replication.
The currently completed retrospective studies and randomized trials have generally shown these findings:
1.when started late in the hospital course and for short durations of time, antimalarials appear to be ineffective
2.when started earlier in the hospital course, for progressively longer durations and in outpatients, antimalarials may reduce the progression of disease, prevent hospitalization, and are associated with reduced mortality …
A typical HCQ regimen is 200 mg bid for 5 days and extended to 30 days for continued symptoms. A minimal sufficient dose of HCQ should be used, because in excessive doses the drug can interfere with early immune response to the virus …
Zinc is a known inhibitor of coronavirus replication … This readily available nontoxic therapy could be deployed at the first signs of COVID-19. Zinc lozenges can be administered 5 times a day for up to 5 days and extended if needed if symptoms persist.
The amount of elemental zinc lozenges is <25% of that in a single 220-mg zinc sulfate daily tablet. This dose of zinc sulfate has been effectively used in combination with antimalarials in early treatment of high-risk outpatients with COVID-19.”
It’s worth noting that in areas where hydroxychloroquine is hard to get a hold of, the nutritional supplement quercetin may be a useful (and perhaps even better) substitute, as its primary mechanism of action is identical to that of the drug. It also has antiviral activi
Article from LewRockwell